In a recent Arthritis & Rheumatology review article, three experts discuss the use of immunosuppressants to target B cells in a patient with systemic sclerosis-interstitial lung disease.
At a ACR Convergence 2025 session, two experts discussed POTS, the importance of considering dysautonomia when making a differential diagnosis & an interdisciplinary approach to treatment.
Experts discuss high-intensity interval training as an underused “disease-modifying drug” for inflammatory diseases. Learn how to safely integrate it into patient treatment plans.
Richard F. Loeser, Jr., MD, MACR, delivering the Oscar Gluck Memorial Lecture at ACR Convergence 2025, discussed research into new treatments for osteoarthritis.
Why do lymphatics fail in inflammatory arthritis? Research from ACR Convergence 2025 points to a network of telocytes & mast cells that control synovial drainage.
This year’s Opening Session of ACR Convergence 2025 featured a well-known thought leader on physician burnout, Dr. Tait Shanafelt, who provided insight into the risk of burnout and how to prevent it. Key leadership also addressed research advocacy and more.
ACR Convergence 2025 experts explore gout’s deep ties to MetS, insulin resistance and cardiovascular mortality, weighing new data on colchicine, febuxostat and SGLT2 inhibitors.
Dr. David Pisetsky curated the research presented at ACR Convergence 2025 and answers the question “What new research on psoriatic arthritis has the potential to impact patient care or future research?”
The ACR honors excellence in rheumatology. Meet the 2025 Awards of Distinction recipients, ACR Masters & Distinguished Fellows recognized at ACR Convergence 2025.